Even HIV-infected individuals who have the greatest challenges in adhering to their antiretroviral (ART) can achieve high adherence on a regimen of one pill taken daily, research shows.
The genomics of resistance to immunodeficiency virus (GRIV) Cohort was established in France in 1995 to generate a large database for genetic studies to identify host genes associated with rapid progression and long-term non-progression to AIDS.
[Editor's note: With the recent news that the U.S. Food and Drug Administration (FDA) has approved a new HIV test that obtains results within one minute, domestic HIV testing and prevention strategies have a new tool to employ. AIDS Alert asked Philip Bligh, president of bioLytical Laboratories in Vancouver, British Columbia and Chicago, IL, to answer questions in writing about his company's INSTI test. His responses are shown in this Q&A story]:
Opt-out HIV testing goals by the Centers for Disease Control and Prevention (CDC) of Atlanta, GA, would have greater success if states were to reduce legislative barriers, an expert says.
Close on the heels of the first positive findings reported in microbicides and vaccine research ventures, the iPrEx study has shown that a pre-exposure prophylaxis (PrEP) combination drug demonstrates 44% additional protection from HIV infection.